Drug Trial Radar · NCT04916470
Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
617
Actual
Start
Jun 15, 2021
Primary completion
Oct 11, 2023
Study completion Oct 11, 2023
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jun 7, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will look at how participants' daily life is affected by their heart failure. The study will also look at the change in participants' body weight. This study will compare the effect of semaglutide (a new medicine) compared to "dummy" medicine on body weight and heart failure symptoms. Participants will either get semaglutide or "dummy" medicine, which treatment participants get is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach area, thigh or upper arm. During the study participants will have talks with the study staff about healthy lifestyle and physical activity. The study will last for about 59 weeks, that is a little more than 1 year. Participants will have 12 clinic visits with the study doctor. * At 6 of the visits participants will have blood samples taken. * At 5 of the visits participants will be asked to fill in a questionnaire * At 4 of the visits participants will have to do a 6-minute walking test * At 3 of the visits participants will have a test to check the heart. * participants will have their eyes checked before or at the start of the study and at the end of the study Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.
Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2
Interventions
SemaglutideDrug
Participants will receive semaglutide subcutaneous (s.c.; under the skin) injection(s) once-weekly for 52 weeks. Dose will be gradually increased to 2.4 mg: 0.25 mg from week 1 to 4, 0.5 mg from week 5 to 8, 1.0 mg from week 9 to 12, 1.7 mg from week 13 to 16 and 2.4 mg from week 17 to week 52.
Placebo (Semaglutide)Drug
Participants will receive semaglutide matching placebo s.c. injection(s) once-weekly for 52 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in KCCQ (Kansas City Cardiomyopathy Questionnaire) Clinical Summary ScoreTime frame: Baseline (week 0), end of treatment (week 52)
- Percentage Change in Body WeightTime frame: Baseline (week 0), end of treatment (week 52)
Locations
180 sites in 16 countries. Site status is shown where the registry gives one.
Eastern Shore Rsrch Inst, LLC
Fairhope, Alabama
Mobile Heart Specialists
Mobile, Alabama
National Heart Institute Cal
Beverly Hills, California
John Muir Physicians Network
Concord, California
Valley Clinical Trials
Covina, California
Keck Medical Center of USC - Outpatient Clinic
Los Angeles, California
Valley Clinical Trials, Inc.
Northridge, California
Lundquist Inst-Biomed Innovtn
Torrance, California
OptumCare Clinical Trials LLC
Golden, Colorado
Excel Med Ctr Clinical Trials
Boca Raton, Florida
Bay Area Cardiology Associates, P.A.
Brandon, Florida
Baptist Heart Specialists_Jacksonville
Jacksonville, Florida
CV Res Ctr of S Florida
Miami, Florida
Endeavor Health Clinical Operations-NCH
Arlington Heights, Illinois
Endeavor Health Glenbook Hosp
Evanston, Illinois
Northwestern University_Chicago_0
Evanston, Illinois
Chicago Medical Research LLC
Hazel Crest, Illinois
Deaconess Specialty Physicians
Evansville, Indiana
Ascension St. Vincent Medical Group
Indianapolis, Indiana
Cardiovascular Rsrch of NW_IN
Munster, Indiana
Cotton-O'Neil Heart Center
Topeka, Kansas
Baptist Health Woodland
Elizabethtown, Kentucky
The Research Group of Lexington LLC
Lexington, Kentucky
Baptist Health Louisville
Louisville, Kentucky
Grace Research, LLC
Bossier City, Louisiana
Heart Clinic of Hammond
Hammond, Louisiana
Clinical Trials of Ame, LLC
Monroe, Louisiana
Grace Research, LLC_Shreveport
Shreveport, Louisiana
Louisiana Heart Center_Slidell
Slidell, Louisiana
Ascension Saint Agnes Heart Ca
Baltimore, Maryland
MedStar Good Samaritan Hosp
Baltimore, Maryland
John Hopkins Hospital
Baltimore, Maryland
Elite Research Center
Flint, Michigan
Mayo Clinic
Rochester, Minnesota
Univ of Mississippi Med Ctr
Jackson, Mississippi
Saint Luke's Hospital of Kansas City
Kansas City, Missouri
St Louis Heart & Vascular, P.C.
St Louis, Missouri
Bryan Heart
Lincoln, Nebraska
CHI Health Clinic Cardiology (CUMC - Bergan Mercy)
Omaha, Nebraska
St Francis Hospital Lindner Research Center
Greenvale, New York
Showing 40 of 180 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.